Actively Recruiting
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-03-13
30
Participants Needed
6
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.
CONDITIONS
Official Title
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant or legally authorized representative can provide written informed consent and privacy authorization before screening
- Age 18 years or older
- Histological or cytological confirmation of prostate cancer
- High-risk localized prostate cancer defined by PSA ≥ 20 ng/ml, or Gleason score ≥ 8, or clinical stage ≥ cT3a
- Candidate for radical prostatectomy as determined by physician
- ECOG performance status of 2 or less
- Normal organ function with specific laboratory values within 28 days prior to registration
- Male participants sexually active with individuals of childbearing potential must agree to use contraception and follow specific guidelines related to sexual activity and sperm donation during and after treatment
You will not qualify if you...
- Evidence of distant metastatic prostate cancer (except N1 disease if planned for surgery)
- Androgen deprivation therapy for more than 4 weeks before consent
- Prior systemic therapy for prostate cancer other than specified ADT
- Previous local therapy to prostate such as radiation or phototherapy
- Poor medical risk due to uncontrolled disorders or recent surgery
- Inability to swallow oral medications or gastrointestinal disorders affecting absorption
- Clinically significant cardiac disease including low ejection fraction, abnormal ECG findings, significant arrhythmias, congestive heart failure, recent myocardial infarction, unstable angina, or uncontrolled hypertension
- Significant venous thromboembolism within 3 months prior to treatment
- Active viral hepatitis (HBV or HCV) with active replication
- Known HIV with recent opportunistic infection or low CD4 count unless well controlled on ART
- Other active malignancies requiring treatment within 3 years except certain skin or bladder cancers
- Use of prohibited medications or investigational agents within specified timeframes
- Known allergy to study compounds
- Any condition that investigator believes would prevent participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
3
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
Commack, New York, United States, 11725
Actively Recruiting
4
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
5
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New York, United States, 10065
Actively Recruiting
6
Memorial Sloan Kettering Nassau (Limited Protocol Activites)
Rockville Centre, New York, United States, 11553
Actively Recruiting
Research Team
K
Kristine Lacuna, MD
CONTACT
D
Dana Rathkopf, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here